Adesão ao tratamento com antineoplásicos orais em pacientes com câncer de mama
Article Sidebar
Main Article Content
Abstract
Objective: to evaluate the adherence associated with factors of oral antineoplastics drugs for patients during breast cancer treatment.Method: A bibliographic survey of studies was performed, considered publications from 2002 to 2018 from Scielo, Pubmed and Lilacs databases. A total of 50articles were selected and after reading the abstracts, 30 studies were selected for full reading. Therefore, those who refer to pharmacotherapeutic monitoring of other diseases not compatible with the present study have been excluded. Of the studies evaluated, 22 addressed the topic of the study and were used as references. With the study, it was plausible to notice that multiple variables are part of the process in the treatment adherence, being that many factors involved are connected to intrinsic elements of the patient itself. However, when the extrinsic factors are analyzed it is possible to conclude that pharmacists’s performance during the dispensation has a big influence in treatment success. The correct and proper dispensing methods are fundamental factors to enhance the treatment adherence for women with breast cancer. Having said that, it can be inferred that continuing education of health professionals working in this very important stage of patient treatment is extremely necessary.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright Statement - Policy Proposal for Open Access Journals
Authors who publish in The Brazilian journal of Biomedical Sciences (RBCBM) agree to the following terms: 1 - Authors retain the copyright and grant the journal the right to first publication, with the work simultaneously licensed under the Creative Commons Attribution License allowing sharing of the work with recognition of the authorship of the work and initial publication in this journal. 2 - Authors are authorized to assume additional contracts separately, for non-exclusive distribution of the version of the work published in this journal (eg, publishing in institutional repository or as a book chapter), with acknowledgment of authorship and initial publication in this journal. 3 - Authors are allowed and encouraged to publish and distribute their work online (eg in institutional repositories or on their personal page) at any point before or during the editorial process, as this can generate productive changes, as well as increase the impact and citation of published work.
This is an open access article under the CC-BY license
(http://creativecommons.org/licenses/by/4.0)
References
WHO. Who Report on Cancer. 2020. License: CC BY-NC-SA 3.0 IGO
OPAS/OMS Brasil - Câncer [Internet]. [cited 2020 May 2]. Available from: https://www.paho.org/bra/index.php?option=com_content&view=article&id=5588:folha-informativa-cancer&Itemid=1094
Tipos de câncer | INCA - Instituto Nacional de Câncer [Internet]. [cited 2020 April 22]. Available from: https://www.inca.gov.br/tipos-de-cancer/cancer-de-mama/profissional-de-saude
Foulon V, Schöffski P, Wolter P. Patient adherence to oral anticancer drugs: An emerging issue in modern oncology. Acta Clin Belg. 2011;66(2):85–96.
Marisa E, Batista M. Avaliação da adesão à terapêutica farmacológica com antineoplásicos orais. 2012; http://hdl.handle.net/10400.6/1092.
Soares Oliveira R, Tenório J, Menezes L, Das Graças M, Gonçalves L. Adesão à Terapia Hormonal Adjuvante Oral em Pacientes com Câncer de Mama. Rev Bras Cancerol. 2012;58(4):593–601.
Marques PAC, Pierin AMG. Fatores que influenciam a adesão de pacientes com câncer à terapia antineoplásica oral. ACTA Paul Enferm. 2008;21(2):323–9.
McDonald ES, Clark AS, Tchou J, Zhang P, Freedman GM. Clinical diagnosis and management of breast cancer. J Nucl Med. 2016;57:9S-16S.- DOI: 10.2967/jnumed.115.157834
Echavarria, I., López-Tarruella, S., Márquez-Rodas, I., Jerez, Y., & Martin, M. (2017). Neratinib for the treatment of HER2-positive early stage breast cancer. Expert Review of Anticancer Therapy, 17(8), 669–679.-DOI: 10.1080/14737140.2017.1338954
Reinert T, de Paula B, Shafaee MN, Souza PH, Ellis MJ, Bines J. Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer. Chinese Clin Oncol. 2018;7(3).-DOI: 10.21037/cco.2018.06.06
Product Information: Faslodex (R), fulvestrant. AstraZeneca Pharmaceuticals, Wilmington, Delaware, 2002. (Mecanismo de ação fulvestranto)
BRASIL. Protocolos clínicos e diretrizes terapêuticas em oncologia. Ministério Da Saúde [Internet]. 2014;1:356. Available from: http://old.cremerj.org.br/publicacoes/148.PDF
Borner M, Scheithauer W, Twelves C, Maroun J, Wilke H. Answering Patients’ Needs: Oral Alternatives to Intravenous Therapy. Oncologist. 2001;6(S4):12–6.- DOI: 10.1634/theoncologist.6-suppl_4-12
Guedes JBR, Guerra MR, Alvim MM, Leite ICG. Fatores associados à adesão e à persistência na hormonioterapia em mulheres com câncer de mama. Rev Bras Epidemiol. 2017;20(4):636–49.
Medicamento contra o câncer de uso oral: enfim, o direito reconhecido - Instituto Oncoguia [Internet]. [cited 2020 April 30]. Available from: http://www.oncoguia.org.br/conteudo/medicamento-contra-o-cancer-de-uso-oral-enfim-o-direito-reconhecido/5777/166/#:~:text=Esse documento foi alterado pela,a Lei no 12.880%2F2013
Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;2014(11).
Atkins L, Fallowfield L. Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer [Internet]. 2006 Sep 1 [cited 2020 Oct 3];42(14):2271–6. Available from: http://www.ejcancer.com/article/S0959804906002097/fulltext
Lam, W. Y., and Fresco, P. (2015). Medication adherence measures: an overview. Biomed. Res. Int. 2015:217047. doi: 10.1155/2015/ 217047
Eraso, Yolanda. (2019). Oncologists’ perspectives on adherence/non-adherence to adjuvante endocrine therapy and management strategies in woman with breast câncer. Patiente Prefer Adherence. PMCID: PMC6681570. DOI:10.2147/PPA.S211939
Jacobs, J. M., Pensak, N. A., Sporn, N. J., MacDonald, J. J., Lennes, I. T., Safren, S. A., Pirl, W. F., Temel, J. S., & Greer, J. A. (2017). Treatment satisfaction and adherence to oral chemotherapy in patients with cancer. Journal of Oncology Practice, 13(5), e474–e483. DOI:10.1200/JOP.2016.019729
Farmácia Clínica - Segurança Na Prática Hospitalar - Fabio Teixeira Ferracini, Wladmir Mendes Borges Filho - Google Livros [Internet]. [cited 2020 April 30]. Available from: https://books.google.com.br/books?id=lDGfpwAACAAJ&dq=farmácia+clinica+segurança+na+prática+hospitalar&hl=pt-BR&sa=X&ved=2ahUKEwiT6eueiJnsAhVsHLkGHTxIDVcQ6AEwAHoECAAQAQ
Oliveira, Amanda de Teixeira; Queiroz AP de A. Perfil de uso da terapia antineoplásica oral: a impotância da orientação farmacêutica. Rev Bras Farmácia Hosp e Serviços Saúde. 2012;3:24–7.